Skip to main content
. Author manuscript; available in PMC: 2021 Jul 22.
Published in final edited form as: Naunyn Schmiedebergs Arch Pharmacol. 2013 Dec 22;387(4):329–339. doi: 10.1007/s00210-013-0950-4

Fig. 5.

Fig. 5

IL-6 protein production in response to non-selective, Epac selective, or PKA selective cAMP analogs. BSMC were treated with the indicated concentration of either 8-Br-cAMP (non-selective), 8-CPT-2Me-cAMP (Epac selective), or 6-Bnz-cAMP (PKA selective) for 24 h and IL-6 in culture supernatant was measured by ELISA. Dashed line represents vehicle. Mean ± SEM, n=3–4 * indicates p<.05 compared to vehicle